Quick Answer
VOLITIONRX LTD reported R&D Expense of $10.08 million for fiscal year 2025.
VOLITIONRX LTD R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.08M | -30.0% |
| 2024 | $14.41M | -26.3% |
| 2023 | $19.55M | +27.5% |
| 2022 | $15.33M | +17.7% |
| 2021 | $13.02M | -10.4% |
| 2020 | $14.53M | +40.2% |
| 2019 | $10.36M | -5.0% |
| 2018 | $10.91M | +35.9% |
| 2017 | $8.03M | +1.5% |
| 2016 | $7.90M | +29.6% |
| 2015 | $6.10M | +50.9% |
| 2014 | $4.04M | +61.5% |
| 2013 | $2.50M | -9.7% |
| 2012 | $2.77M | +82.3% |
| 2011 | $1.52M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.29M | -34.2% | -16.0% |
| June 30, 2025 | $2.72M | -26.8% | +4.3% |
| March 31, 2025 | $2.61M | -43.7% | -24.9% |
| September 30, 2024 | $3.47M | -25.3% | -6.5% |
| June 30, 2024 | $3.72M | -31.8% | -19.7% |
| March 31, 2024 | $4.63M | -5.6% | -0.5% |
| September 30, 2023 | $4.65M | +16.2% | -14.7% |
| June 30, 2023 | $5.45M | +66.2% | +11.1% |
- VOLITIONRX LTD showed a decrease of -30.0% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, VOLITIONRX LTD’s r&d expense has grown by 562.8% (from $1.52 million to $10.08 million).
- The most recent figure is from VOLITIONRX LTD’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: